Advances in Urology

Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back


Publishing date
15 Jan 2012
Status
Published
Submission deadline
15 Jul 2011

1Department of Urology, Kinki University School of Medicine, Osakasayama, Osaka, 589-8511 Japan

2Prostate Cancer Research, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4101, Australia

3Department of Experimental Urology, University Medical Center, 6525 Nijmegen, The Netherlands

4Department of Surgery, University of Toronto, Division of Urology, Sunnybrook Health Sciences Center, Toronto, ON, Canada M4N 3M5


Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back

Description

Recent advances in the fields of genomics, proteomics, pharmacogenomics, and immunology have ushered in a new era in personalized medicine promising more effective and well-tolerated treatments for cancer patients. With continued progress, patients suffering from urological cancer would be excellent candidates to receive benefits from such treatments making personalized therapy a reality.

Although modest achievements have been produced, much is yet to be actualized in order to consider personalized medicine in urological malignancies a success. However, the complexity of the disease process, limited availability of predictive and prognostic biomarkers, and variability in individual responses and eventual relapses add to the challenges that clinicians and researchers must tackle in order to make the dream a reality.

Therefore, it is eminent for the success of personalized medicine to rely on a cross-disciplinary approach that requires the integration between different scientific disciplines and interactions between the research scientists, biostatisticians, and physicians. Using this “systems biology” approach, a new perspective is achieved that may better help us address basic and translational advances that will then be tested and assessed clinically generating feedback to the research scientist.

With this theme in mind, we invite authors to submit original and review articles that will focus on the current state and major advances towards the concept of personalized cancer medicine for urological cancers with an emphasis on prediction, treatment, and prevention. Potential topics include, but are not limited to:

  • Molecularly targeted therapy
  • Vaccine therapy
  • Gene therapy
  • New and emerging technologies
  • Biomarkers (predictive, prognostic, and diagnostic)
  • Proteomics
  • Genomics
  • Pharmacogenomics
  • Targeted chemoprevention

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/au/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 298105
  • - Editorial

Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back

Hirotsugu Uemura | Colleen Nelson | ... | Laurence Klotz
  • Special Issue
  • - Volume 2012
  • - Article ID 248607
  • - Review Article

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer

Jennifer H. Gunter | Amy A. Lubik | ... | Colleen C. Nelson
  • Special Issue
  • - Volume 2012
  • - Article ID 978531
  • - Review Article

Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

Xiaoyu Hou | Thomas W. Flaig
  • Special Issue
  • - Volume 2012
  • - Article ID 419348
  • - Review Article

Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway

Marco A. De Velasco | Hirotsugu Uemura
  • Special Issue
  • - Volume 2012
  • - Article ID 364919
  • - Review Article

Progress in Personalizing Chemotherapy for Bladder Cancer

James S. Chang | Primo N. Lara | Chong-Xian Pan
  • Special Issue
  • - Volume 2012
  • - Article ID 530121
  • - Review Article

The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases

Faris Azzouni | Alejandro Godoy | ... | James Mohler
  • Special Issue
  • - Volume 2012
  • - Article ID 374805
  • - Research Article

Correlation of Gleason Scores with Diffusion-Weighted Imaging Findings of Prostate Cancer

Rajakumar Nagarajan | Daniel Margolis | ... | M. Albert Thomas
  • Special Issue
  • - Volume 2012
  • - Article ID 812398
  • - Review Article

A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy

Atsunari Kawashima | Hitoshi Takayama | Akira Tsujimura
Advances in Urology
 Journal metrics
Acceptance rate17%
Submission to final decision62 days
Acceptance to publication42 days
CiteScore2.900
Impact Factor-
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.